Invited onto Panel about Managing Canadian Healthcare Companies for Growth
TORONTO, January 29, 2018 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces its participation as a panelist and exhibitor at the Cantech Investment Conference, being held at the Metro Toronto Convention Centre on January 31, 2018.
Celebrating its fifth anniversary, Cantech is Canada’s largest technology investment conference. Cantech works to connect approximately 3,500 engaged investors with over 100 leading technology-oriented growth companies. Further information about Cantech is available at www.cambridgehouse.com.
Microbix’ CEO, Cameron Groome, will participate in a panel discussion entitled “Challenges and Triumphs: CEO’s Managing Canadian Healthcare Companies for Growth.” The panel will be moderated by Mr. Eden Rahim of Next Edge Capital and is scheduled for 3pm EST in the main TSX presentation hall.
Microbix will also be exhibiting at the Cantech Conference, to address investor questions about the company, its diagnostic and quality products and its development projects. Microbix will occupy booth 303 at the conference, alongside other exhibiting Canadian growth companies and service providers.
Current Microbix information, including its corporate slide deck, is available from www.microb.wpengine.com.
About Microbix Biosystems
Microbix Biosystems Inc. specializes in the development of proprietary biological and technology solutions for human health and well-being. The Company manufactures a wide range of critical biological materials for the global diagnostics industry, notably antigens used in immunoassays or quality assessment and proficiency testing products. Microbix’ products are sold to more than 100
customers worldwide, primarily to multinational diagnostics companies and laboratory accreditation organizations.
The Company also applies its biological expertise and technology platforms to create other innovative products and technologies. Currently it is commercializing two such proprietary products, (1) Kinlytic® urokinase, a biologic thrombolytic drug used to treat blood clots and (2) LumiSort™ cell-sorting, a technology platform for ultra-rapid and efficient sorting of somatic cells that can be used to enrich cell populations of interest, such as in sexing semen. Established in 1988, Microbix is a publicly traded company, listed on the Toronto Stock Exchange and headquartered in Mississauga, Ontario, Canada.
This news release includes “forward-looking information,” as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, information about the Cantech conference or comments made there, and information about the Company’s biologicals business and its products, development projects, financial results and outlook, as well as risks associated with finances or their stability, operations in foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and product delivery), foreign currency and exchange rates, maintaining adequate working capital or raising further capital on acceptable terms or at all, and any other statements concerning anticipated future events, conditions or results
that are not historical facts. Forward-looking statements reflect management’s current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain and that actual performance may be affected by a number of
material factors, many of which are beyond the Company’s control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in
the forward-looking information. All statements are made as of the date of this news release and represent the Company’s judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information.
Please visit www.microb.wpengine.com or www.sedar.com for recent Microbix filings.
For further information, please contact:
Cameron L. Groome, CEO
Jim Currie, CFO
Deborah Honig, Investor Relations – Adelaide Capital Markets
(647) 203-8793 firstname.lastname@example.org
Copyright © 2018 Microbix Biosystems Inc.
Microbix®, Kinlytic® and LumiSort™ are trademarks of the Company